Stay updated with breaking news from Relational Commerce. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Q1 total revenue of $49.3 million, a YoY increase of 95.3%. - Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%. - Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU... | May 9, 2023
Revance Therapeutics, Inc. , today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and... | March 30, 2023
Received FDA approval for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar linesQ3 total revenue of $29.0 million, a YoY increase of 47% with RHA® Collection revenue of $26.1 million, a YoY increase of 43%Aesthetic accounts across products and services totaled over 4,500 at quarter-en...
GuruFocus Article or News written by Business Wire and the topic is about:
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace